

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 26 February 2004 (26.02.2004)

(10) International Publication Number WO 2004/016317 A1

(51) International Patent Classification7: 35/02, A61K 39/395, C07K 14/47

A61P 35/00,

(21) International Application Number:

PCT/NL2003/000583

(22) International Filing Date: 14 August 2003 (14.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

02078358.5 10/252,132

14 August 2002 (14.08.2002) 19 September 2002 (19.09.2002)

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

10/252,132 (CIP) Filed on 19 September 2002 (19.09.2002)

(71) Applicant (for all designated States except US): ERAS-MUS UNIVERSITY MEDICAL CENTER ROTTER-DAM [NL/NL]; Dr. Molewaterplein 50, NL-3015 GD Rotterdam (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TOUW, Ivo, Paul [NL/NL]; Larikslaan 156, NL-3053 LE Rotterdam (NL). DELWEL, Hendrik, Rudolf [NL/NL]; Leeuwendaal 10, NL-3273 XD Westmaas (NL). LOWENBERG, Bob [NL/NL]; Vijverweg 38, NL-3062 JP Rotterdam (NL).

VALK, Peter, Jacobus, Maria [NL/NL]; Stekelbrem 66, NL-3068 TD Rotterdam (NL).

- (74) Agent: PRINS, A.W.; Nieuwe Parklaan 97, NL-2587 BN Den Haag (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF MURINE GENOMIC REGIONS IDENTIFIED TO BE INVOLVED IN TUMOR DEVELOPMENT FOR THE DEVELOPMENT OF ANTI-CANCER DRUGS AND DIAGNOSIS OF CANCER

(57) Abstract: The present invention relates to murine genomic regions, identified by retroviral insertional tagging of mice as being involved in tumor development, in particular leukemia development, as well as human homologues thereof, and to the use of these genomic regions for the identification and development of anti-cancer drugs, such as small molecule inhibitors, antibodies, ribozymes, antisense molecules and RNA interference (RNAi) molecules, that are effective in reducing or eliminating the tumorigenic effects of genetic transformations in these genomic regions and/or eliminating the tumorigenic effects of expression products thereof. The invention further relates to these anti-cancer drugs and to their use as pharmaceutical reagents for the treatment of cancer, as well as to pharmaceutical compositions comprising one or more of said pharmaceutical reagents and to methods for the treatment of cancer using said pharmaceutical compositions, in particular to methods of gene therapy. In yet further aspects, the invention relates to nucleic acids, to antibodies capable of binding specifically to murine genomic regions and to expression products thereof, to the use of said nucleic acids or antibodies as diagnostic reagents for the diagnosis of cancer, as well as to diagnostic compositions comprising one or more of said diagnostic reagents and to methods for the diagnosis of cancer using said diagnostic compositions.

